18,516 research outputs found
Is sea-basing a viable method of providing logistic support to the UK amphibious force?
No full textMaritime power has traditionally been a central part of the UK’s defence planning and is well
suited to supporting a wide range of military operations. The littoral area has always created
problems for naval planners as most landings historically have had to endure a tactical
separation of the naval and land components, and hence an artificial seam between the Navy
and the Marines. With the end of the Cold War, amphibious operations are going to be more
difficult to conduct than in the past, and amphibious forces are going to have to adopt
manoeuvre warfare capabilities in order to successfully complete their missions. It is very
likely that amphibious forces will have to conduct operations against a numerically superior
enemy, who is on his own terrain, and be surrounded by a neutral, if not hostile populace. As
such, the concept of Operational Manoeuvre From The Sea (OMFTS) whereby the sea is used
as a manoeuvre space, and command and control is fast enough to cope with large amounts of
information, but at the same time allow subordinates maximum flexibility to use their
initiative, is increasingly attractive. It will be important not only for the combat elements to be
able to use this new concept, but the Combat Service Support (CSS) elements as well
<book>
No full textXML wordt in veel situaties gebruikt, en voor dat gebruik worden talloze tools gebouwd. Er zijn verschillende manieren om XML-tools te ontwikkelen, en dit artikel behandelt de voor- en nadelen van de verschillende alternatieven. XML en XML-tools De uitgever Kluwer biedt verschillende soorten informatie aan, zoals wetteksten en belastinggidsen. Deze informatie heeft vaak een vaste structuur: een wet heeft bijvoorbeeld altijd een nummer, en een belastinggids beschrijft componenten die voorkomen op het inkomstenbelastingformulier. De structuur verschilt echter van informatiesoort tot informatiesoort. Voor de beschrijving van een document van dit soort structuren gebruikt Kluwer de Extensible Markup Language (XML) [6], en voor de beschrijving van een structuur zelf een Document Type Definitions (DTD) of een Schema. Een manier om de populariteit van een onderwerp te bepalen is Google te vragen hoe vaak een term voorkomt op het Web, of eigenlijk, in de databases van Google. Zo komen de Beatles bijna 3 miljoen keer voor, en ABBA honderdduizend keer. XML komt ongeveer 20 miljoen keer voor, en verslaat daarmee alle programmeertalen behalve Java. Een andere populariteitsmaat is het aantal vierkante meters boekenplank dat in beslag wordt genomen door boeken over het onderwerp in een academische boekhandel. In mijn lokale boekhandel verslaat XML menig andere nieuwe technologie. Maar wat is XML? XML is een eenvoudig, flexibel tekstformaat, dat veel gebruikt wordt voor het uitwisselen van data op het internet, maar ook tussen bedrijven onderling, en tussen bedrijven en hun klanten. Hier is een voorbeeld van een XML document
ClueS Collusive Stealing Framework
No full text<p>Please check the code here for now (anonymous git repository): </p><p>https://anonymous.4open.science/r/federated-stealing-D782/README.md</p>
Fabrication of Nanoslits with <111> Etching TSWE Method
No full textIn this paper, we report a modified three step anisotropic wet etching (TSWE) method to fabricate solid-state silicon nanoslits. The slit-opening process is performed by <111> crystal plane etching. The etching rate of the <111> crystal plane is reasonably slow as it is only 1/45 of the <100> etching rate, thus allowing and therefore good slits-opening controllability. By slowly etching the <111> crystal plane, the over-etching was effectively reduced. Perfectly rectangular nanoslits with different dimensions were successfully obtained. The smallest achieved feature size of the nanoslit is 8.3 nm.Green Open Access added to TU Delft Institutional Repository ‘You share, we take care!’ – Taverne project https://www.openaccess.nl/en/you-share-we-take-care Otherwise as indicated in the copyright section: the publisher is the copyright holder of this work and the author uses the Dutch legislation to make this work public.Electronic Components, Technology and Material
Abstract P1-10-10: Tumor infiltrating lymphocytes (TILS) among high risk for recurrence breast cancer patients treated with tetrathimolybdate (TM)
No full textAbstract
Background: Tumor infiltrating lymphocytes (TILs) evaluated in the primary tumor biopsy or surgical resection have been well established as having prognostic significance in patients with triple negative breast cancer (TNBC) and HER2+ breast cancer treated with adjuvant chemotherapy (Savas et. al, Nat Rev Clin Oncol 2016). In TNBC, stromal TILs behave as a continuous variable with every 10% increase in TIL resulting in a decrease in risk of recurrence and death. The definition of lymphocyte-predominant breast cancer (LPBC) has been used for tumors that contain 50%–60% TILs and usually have a particularly good outcome (Salgado et al, Ann Oncol 2015). Our group recently demonstrated in a phase II single arm study that tetrathimolybdate (TM), a copper-depleting agent, resulted in improved event free survival (EFS) for TNBC patients compared to historical controls. The 2-year event-free survival (EFS) for stage 2-3 and stage 4 NED was 91% and 67%, respectively. In this analysis, our goal was to explore whether the encouraging results we observed were influenced by enrolling TNBC patients with better prognostic factors at initial diagnosis, namely higher stromal TIL score, in our copper depletion trial.
Methods: Archived primary breast tissue was available from 67 of the 75 patients enrolled in the phase II TM trial. The phase II study included patients with stage II TNBC or stage III or IV NED breast cancer patients, who were treated with TM for 2 years or until relapse. Here we focused on the 30 patients with TNBC. The demographic data for the patients is included in the following table.
Patient DemographicsAge at diagnosisStage at study entryPrior Adjuvant or Neoadjuvant therapyNumber of prior chemotherapy regimens in metastatic setting%Tumor Infiltrating Lymphocytes504Adjuvant110543AAdjuvantn/a30563AAdjuvantn/a20513CNeoadjuvantn/a&lt;5454Adjuvant230514Neoadjuvant210363CAdjuvantn/a20592BAdjuvantn/a60453CAdjuvantn/a&lt;5544Adjuvant130443CNeoadjuvantn/a20474Adjuvant020563CNeoadjuvantn/a10512AAdjuvantn/a10583AAdjuvantn/a20654None25513CNeoadjuvantn/a50503CNeoadjuvantn/a30543CNeoadjuvantn/a10542AAdjuvantn/a20403CNeoadjuvantn/a40604Adjuvant160564None160554Adjuvant010633CNeoadjuvantn/a5424Adjuvant050454Adjuvant110463AAduvantn/a10523CNeoadjuvantn/a10514Adjuvant1&lt;5
The number of TILs in each sample was calculated by an experienced pathologist using published criteria (Salgado et al, Ann Oncol 2015). We used TILs &gt;50% to define LPBC.
Results: Overall, we found that only 3/30 (10%) of TNBC patients had TILs &gt;50%. In addition, 14/30 (46.7%) of TNBC patients had tumors with &lt;10% TILs. The 2-year EFS for the patients with TILs &gt;10% v. &lt;10% was 76.9% v. 69.8%, respectively. (P=0.65)
Conclusions: Only 10% of TNBC patients enrolled in the study had LPBC at diagnosis thus indicating that this cohort was not enriched for patients with immunogenic tumors. When stratified by TILs &gt;10% or &lt;10%, there was no statistically significant difference in EFS. Although the analysis is limited due to the small sample size, it does suggest that the amount of TILs present at initial diagnosis did not influence the overall outcome for patients treated with TM.
Citation Format: Rybstein MD, Nackos E, Kornhauser N, Cigler T, Andreopoulou E, Moore A, Cobham M, Fitzpatrick V, Demaria S, Vahdat LT. Tumor infiltrating lymphocytes (TILS) among high risk for recurrence breast cancer patients treated with tetrathimolybdate (TM) [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P1-10-10.</jats:p
MULTIFRACTAL q RÉNYI DIMENSIONS OF POLISH SPACES FOR q < 1
No full text In earlier work the second author investigated the multifractal q Rényi dimensions of Polish spaces for q ≥ 1. In this paper we complement those results by investigating the multifractal q Rényi dimensions of Polish spaces for q < 1. </jats:p
ARRIVE Guideline - Full Author checklist
No full text<p>ARRIVE Guideline - Full Author checklist </p>
Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer
No full textPURPOSE:
Ixabepilone (BMS-247550) is an epothilone analog that optimizes the properties of naturally occurring epothilone B. Natural epothilones and their analogs promote tumor cell death by binding to tubulin and stabilizing microtubules, causing apoptosis. This international phase II trial assessed the activity of ixabepilone in patients with metastatic breast cancer (MBC) that was resistant to taxane therapy.
PATIENTS AND METHODS:
MBC patients, who had experienced disease progression while receiving or within 4 months of taxane therapy (6 months if adjuvant taxane only), and who had a taxane as their last regimen, received ixabepilone (1- or 3-hour infusion of 50 mg/m(2) or 3-hour infusion of 40 mg/m(2) every 3 weeks).
RESULTS:
Of 49 patients treated with 40 mg/m(2) ixabepilone during 3 hours, 35 (73%) had experienced disease progression within 1 month of their last taxane dose. The response rate was 12% (95% CI, 4.7% to 26.5%). All responses (n = 6) were partial; five of six patients had not responded to prior taxane therapy. In responders, the median response duration was 10.4 months. In 20 patients (41%), stable disease was the best outcome. Median time to progression was 2.2 months (95% CI, 1.4 to 3.2 months); median survival was 7.9 months. For treated patients across all cohorts (intent-to-treat population), the response rate was also 12% (eight of 66). Treatment-related adverse events in the study were manageable and primarily grade 1/2. Treatment-related neuropathy was mostly sensory and mild to moderate.
CONCLUSION:
Ixabepilone (40 mg/m(2) as a 3-hour infusion every 3 weeks) demonstrates promising antitumor activity and an acceptable safety profile in patients with taxane-resistant MBC
- …
